#United States #New Jersey #Class Action #Securities Fraud #ADMA Biologics

Recent Developments in ADMA Biologics Securities Fraud Case

In a significant turn of events for investors, ADMA Biologics, Inc. is currently embroiled in a class action lawsuit alleging securities fraud. The lawsuit was initiated following a substantial drop in the company's stock price, which fell by 29% due to accusations from Culper Research regarding misleading business practices, notably allegations of channel stuffing.

Background of the Case

ADMA Biologics is recognized as a commercial biopharmaceutical company, primarily focused on the development and distribution of specialty biologics, including its leading product, ASCENIV. This immune globulin solution is intended for treating Primary Humoral Immunodeficiency in both adults and adolescents. However, recent claims have raised eyebrows about the company's revenue reporting methods.

The legal actions stem from allegations that ADMA falsely reported a 20% growth in 2025, which was allegedly inflated due to a deceptive channel stuffing scheme. According to the claims, ADMA induced its distributors to overstock ASCENIV by providing rebates and extended payment terms. By doing so, the company was able to book revenue that arguably did not reflect actual sales. Critically, it was suggested that had these practices not been in play, the firm would have reported a 3% decline rather than the touted growth.

The Initial Stock Drop

On March 24, 2026, the ramifications of these practices became evident as ADMA's stock plummeted by 16.6%, closing at $11.33 per share from a previous close of $13.59. The decline was further exacerbated when additional reports emerged, including one from Investing.com that indicated a downgrade of ADMA’s stock rating based on the ongoing concerns related to the allegations.

Following these developments, ADMA’s stock suffered further, finishing at $9.63 on March 25, 2026, and subsequently dropping to $8.29 by March 29, 2026.

Upcoming Legal Action and Deadlines

The litigation is currently pending in the U.S. District Court for the District of New Jersey, and the case is identified as Mazzarino v. ADMA Biologics, Inc., et al. No. 26-cv-6918. Investors are encouraged to participate actively in the case, as they have until August 10, 2026, to apply to take the lead in the lawsuit. This deadline is crucial for those who may want to assert their rights as shareholders under the provisions of the Securities Exchange Act of 1934, specifically sections 10(b) and 20(a).

What Should Investors Do?

For investors in ADMA Biologics, the implications of the lawsuit could be significant. Those who have been impacted by the share price decline might have legal recourse through this class action. Bleichmar Fonti & Auld LLP, the firm leading this legal initiative, operates on a contingency fee basis, meaning shareholders will not incur upfront legal expenses. They will seek court approval for any fees or costs related to the litigation.

Interested shareholders should visit the law firm's website at BFA Law for further information and to submit their details if they wish to participate. The firm is widely recognized in the field for its successful track record in securities litigation, having recovered substantial amounts for plaintiff investors in similar cases.

As the situation with ADMA Biologics unfolds, investors must stay informed and consider their options regarding potential claims associated with this alarming case of alleged securities fraud. Immediate action is recommended as the August 10 deadline approaches, shaping the landscape for affected shareholders.